The company said no safety concerns were identified in patients, adding that it intends t submit marketing applications to the US Food and Drug Administration before the end o 2023, with regulatory filings in additional markets to follow in 2024
BridgeBio Pharma Inc said on Monday its experimental drug to treat a kind of heart disease showed statistically significant improvement in reducing hospitalisations in a late-stage study, sending shares up 64 per cent.
The company said no safety concerns were identified in patients, adding that it intends to submit marketing applications to the US Food and Drug Administration before the end of 2023, with regulatory filings in additional markets to follow in 2024.
The drug, acoramidis, is being developed to treat a rare disease that can lead to heart failure, the company said.